Phase I study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients (Pts) with refractory solid tumors or lymphoma.

Anthony W. Tolcher,Kyriakos P. Papadopoulos,Amita Patnaik,Wayne J. Fairbrother,Harvey Wong,Nageshwar Budha,Walter C. Darbonne,Franklin Peale,Michael Mamounas,Stephanie Royer-Joo,Ron Yu,Chia C. Portera,Johanna C. Bendell,Howard A. Burris,Jeffrey R. Infante

Phase I study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients (Pts) with refractory solid tumors or lymphoma.

2013

Anthony W. Tolcher
Kyriakos P. Papadopoulos
Amita Patnaik
Wayne J. Fairbrother
Harvey Wong
Nageshwar Budha
Walter C. Darbonne
Franklin Peale
Michael Mamounas
Stephanie Royer-Joo
Ron Yu
Chia C. Portera
Johanna C. Bendell
Howard A. Burris
Jeffrey R. Infante

2503 Background: GDCE0917 is a small molecule that triggers tumor cell apoptosis by selectively antagonizing IAP proteins. Preclinical studies demonstrated antitumor efficacy of GDC-0917 alone or i...

Keywords:

Inhibitor of apoptosis
Lymphoma
Immunology
Pharmacokinetics
Medicine
Refractory
Antagonist
phase i study
in patient
Pharmacology
Small molecule

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations